FHTX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system...

Stats
Dagens volum	47 530.00
Gjennomsnittsvolum	147 690
Markedsverdi	254.97M
EPS	$0 ( 2024-03-14 )
Neste inntjeningsdato	( $-0.550 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.56
ATR14	$0.0800 (1.34%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Humer Kristian	Buy	275 000	Stock Option (Right to buy)
2024-04-16	Humer Kristian	Buy	0
2024-03-11	Cavalie Fanny	Sell	11 000	Common Stock
2024-01-24	Gottschalk Adrian	Buy	300 000	Stock Option (right to buy)
2024-01-24	Cardama Alfonso Quintas	Buy	60 000	Stock Option (right to buy)

INSIDER POWER
43.20
Last 90 transactions
Buy: 4 432 955 \| Sell: 2 595 211

Volum Korrelasjon

Lang: -0.10 (neutral)

Kort: -0.39 (neutral)

Signal:(44.645) Neutral

Foghorn Therapeutics Inc. Korrelasjon

10 Mest positive korrelasjoner
SSRM	0.88
AMRK	0.848
UMPQ	0.829
SSSS	0.812

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Foghorn Therapeutics Inc. Korrelasjon - Valuta/Råvare

-0.44
( neutral )

-0.41
( neutral )

0.00
( neutral )

-0.52
( weak negative )

0.61
( weak )

0.31
( neutral )

Foghorn Therapeutics Inc. Økonomi

Annual	2023
Omsetning:	$34.16M
Bruttogevinst:	$25.49M (74.64 %)
EPS:	$-2.34

FY	2023
Omsetning:	$34.16M
Bruttogevinst:	$25.49M (74.64 %)
EPS:	$-2.34

FY	2022
Omsetning:	$19.23M
Bruttogevinst:	$19.21M (99.90 %)
EPS:	$-2.62

FY	2021
Omsetning:	$1 319.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.00274

Financial Reports:

No articles found.

Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and with Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.